Richard Messmann

Chief Medical Officer Convergent Therapeutics, Inc

Seminars

Tuesday 29th July 2025
Revealing the Lutathera & Pluvicto Stories from Bench to Bedside to Illustrate Prime Radiopharmaceutical Drug Development
8:30 am
  • Exploring chemical structures, medicinal chemistry and delivery mechanisms
  • Understanding key steps for successful translation and early clinical design
  • Assembling the clinical workforce for the path to commercialization
Tuesday 29th July 2025
Question & Answer Session with Radiopharmaceutical Pioneers to Elevate your Industry Understandings
2:30 pm

Join our open session to ask your burning questions to the industry leaders ahead of the main conference to equip your team with expert knowledge ahead of the main conference.

Join this session to ask exactly what you want to know on topics like:

  • R&D and Preclinical: novel target choices, targeting molecules, linkers, chelators, preclinical dosimetry and more
  • CMC and Regulatory: isotope properties, differences in supply chain, logistics networks, CMC innovations, regulatory considerations and more
  • Clinical Development: clinical trial design, working with sites, working with clinical stakeholders, patient centric approaches and more
Thursday 31st July 2025
Panel Discussion: Identifying Delays in Clinical Research to Streamline Development
11:30 am

• Industry-clinic collaborations

• Forward planning to avoid delays

• Accelerating development among nuclear medicine teams

Wednesday 30th July 2025
Panel Discussion: Exploring How Real-World Evidence Can Impact Design of Future RLT Trials
10:00 am

• Using real-world clinical outcomes to provide insights into patient populations, treatment efficacy and long-term safety

• Enhancing trial design through optimal patient selection, dosing strategies and endpoints

• Guiding potential personalized treatment strategies

Tuesday 29th July 2025
Panel Discussion: Commentary on Past & Future Developmental Pathways & Radiopharmaceutical Strategies
9:30 am
  • Delving into the radiopharma landscape and technical development pathways
  • Sharing experiences
Richard Messmann